Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Synteract was a full-service global contract research organization (CRO) dedicated to supporting biopharmaceutical companies in all phases of clinical development. With a strong focus on therapeutic areas such as oncology, central nervous system (CNS), rare and orphan diseases, pediatrics, and dermatology, Synteract offered a comprehensive suite of services including clinical trial management, regulatory affairs, data management, and biostatistics. In 2020, Synteract was acquired by Syneos Health, integrating its expertise and capabilities into a larger global CRO framework. Prior to its acquisition, Synteract was known for its customer-centric approach, therapeutic expertise, and commitment to bringing new medical treatments to patients worldwide.
Served as the main corporate office, directing global CRO operations, strategic planning, business development, financial management, and administrative functions before the Syneos Health acquisition.
The Carlsbad office was likely a modern office facility situated in a business park, designed to foster collaboration and support the complex needs of clinical research operations. Specific architectural details are not widely publicized, but such facilities typically prioritize functionality and a professional environment.
Synteract promoted a work culture centered on scientific rigor, client partnership, quality, and a patient-first mindset. The environment was characterized by collaboration among experts in various therapeutic and operational fields, aiming to accelerate drug development.
The Carlsbad headquarters was pivotal as the nerve center for Synteract's international operations and its growth in the competitive CRO market, particularly for managing North American activities and global strategy.
Prior to its acquisition by Syneos Health, Synteract maintained a robust global presence with offices and operational capabilities across North America, Europe (including Western, Central, and Eastern Europe), and other strategic locations worldwide. This international network enabled Synteract to globally support a comprehensive suite of clinical development services, including multi-regional clinical trial management, project leadership, regulatory strategy and submissions, medical and safety monitoring, biostatistics and programming, clinical data management, site selection and monitoring, and quality assurance programs. Their global footprint was crucial for serving emerging to mid-size biopharma clients with international study needs.
5750 Fleet Street, Suite 220
Carlsbad
CA
USA
Address: Synteract previously maintained a significant operational presence in Munich. Specific historical street addresses may vary post-acquisition.
Central to managing European clinical studies, providing local expertise, and ensuring compliance with regional regulatory frameworks like EMA guidelines.
Address: An office in Prague was part of Synteract's Central/Eastern European network. Specific historical street addresses may vary post-acquisition.
Provided strategic access to diverse patient populations and experienced clinical sites in Eastern European countries, contributing to efficient global trial conduct.
Address: Synteract operated an office in Warsaw to support its Eastern European activities. Specific historical street addresses may vary post-acquisition.
Expanded Synteract's operational footprint in Eastern Europe, supporting a range of clinical research projects in the region.
Address: Synteract had an operational presence in the Research Triangle Park area. Specific historical street addresses may vary post-acquisition.
Strengthened Synteract's service delivery capacity in the U.S., particularly on the East Coast, facilitating collaborations with numerous biopharma clients.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Synteract' leadership includes:
Synteract has been backed by several prominent investors over the years, including:
Synteract was acquired by Syneos Health in 2020 and has since been integrated into Syneos Health's operations. Consequently, there have been no executive hires or exits specifically for 'Synteract' as an independent entity in the last 12 months. Any leadership changes pertinent to former Synteract capabilities would now occur within the Syneos Health organizational structure. The information below reflects this status for the requested 12-month period.
Discover the tools Synteract uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition and integration into Syneos Health, Synteract likely used standard corporate email address formats. Common patterns for companies in the CRO industry include combinations of first name, last name, and initials.
Likely formats included [first_initial][last]@synteract.com (e.g., jsmith@synteract.com) or [first].[last]@synteract.com (e.g., john.smith@synteract.com). Note: The synteract.com domain may no longer be active for email post-acquisition.
Format
jsmith@synteract.com
Example
70%
Success rate
GlobeNewswire • July 1, 2020
Syneos Health announced a definitive agreement to acquire Synteract, a full-service CRO. This strategic acquisition aimed to enhance Syneos Health's capabilities in complex therapeutic areas like CNS, oncology, and rare diseases, and to broaden its reach within the mid-size biopharmaceutical company segment....more
PR Newswire • March 14, 2018
Synteract was recognized as the 'Best Full-Service CRO - USA' in the 2018 Biotechnology Awards by Global Health & Pharma (GHP) Magazine. This award highlighted Synteract's dedication to quality, customer service, and excellence in clinical research services....more
Gryphon Investors • October 4, 2016
Gryphon Investors, a San Francisco-based private equity firm, announced it signed a definitive agreement to acquire SynteractHCR (later known as Synteract). The investment was intended to support the CRO's continued growth, expand its global reach, and enhance its service offerings to biopharmaceutical clients....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Synteract, are just a search away.